Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to sites of inflammation. The recruitment of macrophages to the arterial wall is believed to be a critical step in the development of atherosclerosis.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Plozalizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Plozalizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Plozalizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Plozalizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Plozalizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Plozalizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Plozalizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Plozalizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Plozalizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Plozalizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Plozalizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Plozalizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Plozalizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Plozalizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Plozalizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Plozalizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Plozalizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Plozalizumab. |
| Equol | Equol may increase the thrombogenic activities of Plozalizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Plozalizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Plozalizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Plozalizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Plozalizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Plozalizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Plozalizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Plozalizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Plozalizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Plozalizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Plozalizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Plozalizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Plozalizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Plozalizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Plozalizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Plozalizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Plozalizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Plozalizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Plozalizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Plozalizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Plozalizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Plozalizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Plozalizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Plozalizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Plozalizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Plozalizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Plozalizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Plozalizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Plozalizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Plozalizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Plozalizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Plozalizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Plozalizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Plozalizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Plozalizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Plozalizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Plozalizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Plozalizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Plozalizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Plozalizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Plozalizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Plozalizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Plozalizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Plozalizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Plozalizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Plozalizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Plozalizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Plozalizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Plozalizumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Plozalizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Plozalizumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Plozalizumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Plozalizumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Plozalizumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Plozalizumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Plozalizumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Plozalizumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Plozalizumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Plozalizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Plozalizumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Plozalizumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Plozalizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Plozalizumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Plozalizumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Plozalizumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Plozalizumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Plozalizumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Plozalizumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Plozalizumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Plozalizumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Plozalizumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Plozalizumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Plozalizumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Plozalizumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Plozalizumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Plozalizumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Plozalizumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Plozalizumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Plozalizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Plozalizumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Plozalizumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Plozalizumab. |